Genentech - DNA - Avastin - Herceptin - Rituxan -Tarceva
Genentech - DNA - Avastin - Herceptin - Rituxan -TarcevaGenentech - DNA - Avastin - Herceptin - Rituxan -Tarceva
MSN Money - Briefing.com Business News: Market Report -- Story Stocks (DNA, OSIP, BIIB): US:DNA
Genentech (DNA) 84.45 +0.95: The growth story continues for biotech giant Genentech. Amid ongoing clinical success, the world's second largest biotech company reported fiscal second quarter results well ahead of analysts' expectations. EPS climbed 58% from a year ago to $0.30, while operating revenues increased 35% to $1.53 billion. The results eclipsed the consensus estimates of $0.26 per share on revenues of $1.48 billion as strong sales of the company's cancer treatments broadly contributed to the upside.
Fast growing sales of leading products Avastin, Herceptin, Rituxan, and Tarceva have translated into healthy top line growth
BioTech News at Arizona Biotech
0 Comments:
Post a Comment
<< Home